Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT03983954
Title	Naptumomab Estafenatox in Combination with Durvalumab in Subjects with Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.
Recruitment	Recruiting
Gender	both
Phase	Phase I
Variant Requirements	No
Sponsors	NeoTX Therapeutics Ltd.
Indications	urinary bladder cancer transitional cell carcinoma Her2-receptor negative breast cancer gastroesophageal junction adenocarcinoma head and neck squamous cell carcinoma pancreatic adenocarcinoma prostate cancer hepatocellular carcinoma melanoma ovarian serous carcinoma gastroesophageal cancer esophagus adenocarcinoma triple-receptor negative breast cancer malignant mesothelioma cervical squamous cell carcinoma colorectal cancer renal cell carcinoma endometrial cancer esophagus squamous cell carcinoma lung non-small cell carcinoma
Therapies	Durvalumab + Naptumomab estafenatox Durvalumab + Naptumomab estafenatox + Obinutuzumab
Age Groups:	senior \| adult
Covered Countries	ISR